Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.

Overview

Periodontal disease is an infectious disease resulting in inflammation within supporting tissues of the teeth, progressive attachment loss, and bone loss. Epidemiological studies reveal that about 10% of the adult population suffer from severe periodontitis.It comprises of two distinct but interconnected etiologic components: the periodontopathic bacteria adjacent to the periodontal tissues, and the host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products. In the arena of periodontics, the probiotics pose a great potential of plaque modification, halitosis management, altering anaerobic bacteria colonization, improvement of pocket depth, and clinical attachment gain. Aim of the study is to analyze the beneficial effect of probiotic lozenges as an adjunct to Scaling and Root Planing, on clinical and biochemical parameters.

Full Title of Study: “Effect of Probiotic Lozenges as an Adjunct to Non Surgical Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Double Blind Placebo Controlled Clinical and Biochemical Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 2016

Interventions

  • Drug: Probiotic (Inersan)
    • Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
  • Drug: Placebo
    • Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

Arms, Groups and Cohorts

  • Experimental: Probiotic (Inersan) Arm
    • Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
  • Placebo Comparator: Placebo Arm
    • Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

Clinical Trial Outcome Measures

Primary Measures

  • Improvement in Periodontal Clinical indices
    • Time Frame: 6 weeks
    • Improvement in periodontal clinical indices, namely, Gingival Index (GI), Plaque Index (PI), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).

Secondary Measures

  • Improvement in biochemical indices
    • Time Frame: 6 weeks
    • Changes in level of inflammatory markers namely PGE2, IL-1beta, TNF-alpha, receptor activator of nuclear factor kappa B ligand (RANKL), Osteoprotegerin (OPG), MMP-9 and MMP-13 in saliva sample

Participating in This Clinical Trial

Inclusion Criteria

  • Subject of both sexes – Age group of 25-65 years – Subjects with generalized moderate to severe chronic periodontitis – Signed informed Consent Exclusion Criteria:

  • Any known history of systemic diseases – Patients already on anti-inflammatory drugs or antibiotics – Patients allergic to any material used in the study – Pregnant and lactating women – Periodontal therapy in past 6 months – Current smoker or smoker in the past

Gender Eligibility: All

Minimum Age: 25 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CD Pharma India Pvt. Ltd.
  • Collaborator
    • Government Dental College and Hospital, India
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rohan Sethi, BDS, Principal Investigator, Government Dental College & Hospital, Aurangabad

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.